Clinical trials
Prostate Adenocarcinoma clinical trials
Below are recruiting prostate adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 143 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05113537RecruitingPhase 1/Phase 2
Abemaciclib before PSMA cancer therapy for advanced prostate cancer
This trial tests whether taking abemaciclib before a PSMA-targeted radioligand can help people with advanced, treatment-resistant prostate cancer. The goal is to improve how well the PSMA therapy works while staying safe.
San Francisco, CaliforniaAges 18 years+ - NCT04734730RecruitingPhase 2
Talazoparib plus hormone therapy for metastatic prostate cancer
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
Duarte, CaliforniaAges 18 years+ - NCT05168618RecruitingPhase 2
Cabozantinib and atezolizumab for advanced prostate cancer
This Phase 2 trial tests cabozantinib plus atezolizumab in people with metastatic prostate cancer that keeps growing despite hormone-blocking therapy and newer hormone drugs. It may help shrink tumors and control the disease, especially in advanced cases where options are limited.
Salt Lake City, UtahAges 18 years+ - NCT06915909Recruiting
Robotic prostate surgery with low pressure gas for less pain
This trial tests whether using lower gas pressure during robotic prostate surgery can reduce pain after the operation. It aims to help men recover more comfortably.
Stevenage, HertfordshireAges 18–75 - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Birmingham, AlabamaAges 18 years+ - NCT06330805RecruitingPhase 2
Comparing heart effects of two hormone therapies for prostate cancer
This trial compares two hormone therapies, relugolix and leuprolide, to see which one is better for your heart health in men with prostate cancer. It's for men with a specific type of prostate cancer that is not yet advanced.
Columbus, OhioAges 18 years+ - NCT05574647Recruiting
Fast prostate MRI and guided biopsy testing for prostate cancer
This study checks whether a faster prostate MRI and image-matching (image-fusion) can better find suspicious spots so doctors can target a biopsy. If you have concerning prostate exam results or PSA blood test results, you may get an MRI and, if something looks suspicious, a biopsy using MRI images.
Southend-on-Sea, EssexAges 18 years+ - NCT05001477Recruiting
Registry for men receiving TULSA-PRO prostate treatment
This is a study registry that collects information from men who are going to receive TULSA-PRO treatment. It helps researchers understand how the treatment is used and what outcomes people experience.
West Hills, CaliforniaAges 18 years+ - NCT05665738Recruiting
Two-visit HDR radiation to treat early prostate cancer
This study tests a radiation treatment delivered in two fractions (two sessions) as the only treatment for certain early-stage prostate cancers. It may help you avoid other treatments, like hormone therapy, depending on whether your cancer and health history fit the study.
San Francisco, CaliforniaAges 18 years+ - NCT05616650RecruitingPhase 2
Targeted radiation for one prostate tumor spot
This Phase 2 study tests a focused radiation approach using stereotactic body radiation therapy (SBRT) for people with one prostate tumor visible on imaging. It aims to treat a single tumor area while limiting treatment to the rest of the prostate.
Bethesda, MarylandAges 18–120 - NCT05054296RecruitingPhase 2
Exercise and Fitbit monitoring to lower heart risk in prostate cancer
This Phase 2 study tests whether a structured exercise and lifestyle program, tracked with a Fitbit, can reduce cardiovascular (heart) risk in men with prostate cancer on hormone therapy. It also checks whether this is safe and feasible while monitoring symptoms and fitness changes.
Houston, TexasAges 18 years+ - NCT06325046Recruiting
Adaptive radiation therapy for localized prostate cancer
This trial tests a type of radiation that adapts to your body's changes during treatment. It is for men with low- to intermediate-risk prostate cancer that hasn't spread.
Albert Lea, MinnesotaAges 18 years+ - NCT07426055RecruitingPhase 2/Phase 3
Prostate cancer radiation boost comparison study
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06145633RecruitingPhase 2
Vorinostat and 177Lu-PSMA-617 for PSMA-Low prostate cancer
This trial tests two drugs: vorinostat (a pill that may make cancer cells easier to target) and 177Lu-PSMA-617 (a radioactive drug that seeks out prostate cancer cells). It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and shows low levels of PSMA on a PET scan.
Seattle, WashingtonAges Any age - NCT06173362RecruitingPhase 2
Abiraterone or darolutamide for advanced prostate cancer
This study is comparing two drugs, abiraterone and darolutamide, to see how well they work for advanced prostate cancer. You might join if your cancer has spread and your doctor agrees these treatments could help.
Sacramento, CaliforniaAges 18 years+ - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+ - NCT07468903Recruiting
Focal radiation for prostate cancer with HDR brachytherapy
This trial tests a targeted radiation treatment called HDR brachytherapy for prostate cancer that hasn't spread. It aims to treat only the cancer spots seen on MRI, which may reduce side effects.
Los Angeles, CaliforniaAges 40 years+ - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT06872619Enrolling by invitation
Prostate Cancer Research Registry
This registry collects information from people with prostate cancer to help researchers better understand the disease and improve future treatments.
MünsterAges 45–100 - NCT06236139RecruitingPhase 1/Phase 2
Engineered immune cells plus hormone therapy for advanced prostate cancer
This trial tests a new cell therapy (STEAP1-targeted CAR T cells) combined with the hormone therapy enzalutamide for men with metastatic prostate cancer that has stopped responding to standard treatments. It aims to see if this combination can shrink tumors and slow the cancer.
Seattle, WashingtonAges 18 years+ - NCT05600400Recruiting
Test two vs five MRI-guided treatments for prostate cancer
This trial is comparing two different MRI-guided radiation treatment plans to see which one better improves sexual quality of life in prostate cancer. It may help people decide between shorter or more treatment-session radiation approaches.
Toronto, OntarioAges 18 years+ - NCT06039371RecruitingPhase 2
High dose testosterone during chemo for advanced prostate cancer
This trial tests if adding high doses of testosterone to standard chemotherapy (etoposide and carboplatin) can make the chemo work better in men whose prostate cancer has stopped responding to other treatments. It aims to see if this approach can shrink tumors or slow cancer growth.
Seattle, WashingtonAges 18 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Tucson, ArizonaAges 18 years+ - NCT03880422Recruiting
Exercise and nutrition for weight and frailty after prostate cancer treatment
This study tests whether a structured exercise and nutrition program can improve obesity-related frailty and overall function in people with advanced prostate cancer who are taking hormone therapy (ADT). It may help with strength, mobility, and healthier body weight during/after ADT.
Buffalo, New YorkAges 18 years+
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate adenocarcinoma?
- Yes. Clin2 currently lists 143 recruiting prostate adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.